Bennink, Christine http://orcid.org/0000-0001-8700-8598
de Mul, Marleen
van der Klift, Marjolein
Broijl, Annemiek
Tick, Lidwine
de Jongh, Eva
Garvelink, Mirjam
Lobbezoo, Dorien
Sonneveld, Pieter
Hazelzet, Jan
Funding for this research was provided by:
Zorginstituut Nederland (OP1240)
Article History
Accepted: 17 January 2023
First Online: 15 February 2023
Declarations
:
: This study received funding from the National Health Care Institute (Zorginstituut Nederland), OP1240.
: PS received research grants from Amgen, Celgene, Janssen and Skyline Dx, honoraria from Amgen, BMS/Celgene, Janssen, Karyopharm and Seagen, and is the Chairman of the European Myeloma Network and Co-Chairman of HOVON Myeloma Working Group. JH is an independent consultant. AB is on the advisory boards and has received honoraria from Amgen, Janssen, BMS and Sanofi. CB, MM, MK, LT, EJ, MG and DL have no conflicts of interest that are directly relevant to the content of this article.
: Ethics approval was not required (MEC-2022-0001).
: Written consent was obtained from all patients, verbal consent was obtained from all other participants prior to the interview.
: All participants provided verbal consent for publication.
: The datasets generated and analysed during the current study are available from the corresponding author upon reasonable request.
: Not applicable.
: CB, MdM, DL, PS and JH contributed to the conception and design. CB, MvdK, AB, LT, EdJ and MG participated in the data collection. CB, MdM and JH performed the analysis and drafted the first version of the manuscript. All authors critically read, revised and approved the final version of the manuscript.
: Written consent was obtained from all patients, verbal consent was obtained from all other participants prior to the interview. All participants provided verbal consent for publication.